ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ipsen and Debiopharm side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

IpsenDebiopharm
studies on the registry35752
open to participants now256
phase 3 studies under way162
reach primary completion within a year141
programswith a study of their own in two years94

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseIpsenDebiopharm
Phase 1

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%

Debiopharm: 1 of its 4 programs at phase 1

  1. DEBIO 1453Pphase 1
25%
Phase 244%

Debiopharm: 2 of its 4 programs at phase 2

  1. afabicinphase 2
  2. Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562Mphase 2
50%
Phase 3

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%

Debiopharm: 1 of its 4 programs at phase 3

  1. Octreotide Sustained-release Formulation Debio 4126phase 3
25%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ipsen3 readouts · 1 phase 3·

Ipsen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. elifibranorphase 3 · Dec 17 · NCT06730061
··

Ipsen, Mar ’27: 1 program whose next study reaches primary completion

  1. corabotasephase 3 · Mar 26 · NCT06937931
······

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
Debiopharm1 readouts · 0 phase 3·

Debiopharm, Dec ’26: 1 program whose next study reaches primary completion

  1. DEBIO 1453Pphase 1 · Dec 0 · NCT07035769
··········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Debiopharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionIpsenDebiopharm
Leukemia, Myeloid, Acuteboth · compare here

Ipsen in Leukemia, Myeloid, Acute: 1 program

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3

Their studies: Ipsen’s studies of Leukemia, Myeloid, Acute in search

Renal Insufficiencyboth · compare here

Ipsen in Renal Insufficiency: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Renal Insufficiency in search

Debiopharm in Renal Insufficiency: 1 program

  1. afabicinphase 2

Their studies: Debiopharm’s studies of Renal Insufficiency in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Ipsen 4 of 9 · Debiopharm 2 of 4 programs (5 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.